Abstract
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation treatment for major depressive disorder. Randomized controlled trials show response rates twice times higher for TMS (23.9%) than placebo (12.3%) in adults with depression. Real world studies showed increased response rates up to 58% in clinically heterogenous adult patient populations.
TMS is safe and well tolerated with a benign side effect profile and high adherence. Standard TMS protocols include left dorso-lateral prefrontal cortex stimulation using a fixed stimulation protocol or burst-patterned protocols such as intermittent theta burst delivered over six weeks. Novel accelerated protocols using high daily dosing and functional MRI targeting provide increased precision and improved treatment outcomes. TMS shows effectiveness in patients with comorbid anxiety, older adults and adolescents for which received FDA approval in 2024.
Future studies incorporating neuroimaging techniques may help to refine protocols leading to improved outcomes across different patient populations.
Keywords: Transcranial magnetic stimulation, brain stimulation, neuromodulation, depression, depression treatment algorithm
Introduction
TMS is an office based, non-invasive brain stimulation technique that uses strong (1.5 – 3 Tesla) but focused magnetic fields to modulate brain activity. TMS devices use the electromagnetic induction principle in which passing an electrical current through a coil of wire generates a magnetic field. The dynamic, rapidly changing magnetic field originated in the TMS coil in turns generates electrical activity on a nearby conductor. When the TMS coil is in contact with the scalp it induces neuronal depolarization on a focal area of the brain cortex; these effects propagate downstream affecting neural pathways in distant brain regions.1
TMS was first introduced in the UK by Antony Barker,2 after years of active research TMS received approval by the US FDA in 2008 for treating Major Depressive Disorder (MDD) in adult patients who have not responded to antidepressant medications, or those with medication intolerance.3 In March, 2024 TMS was also approved for the treatment of adolescent depression.3 Other FDA indications also include Obsessive Compulsive Disorder and smoking cessation, although these involve different TMS coils and protocols (Figure 1).
Figure 1.
Clinical administration of Transcranial Magnetic Stimulation at Washington University’s Treatment-Resistant Depression Program in St. Louis, Missouri, USA.
We provide an overview of TMS for the non-psychiatrist to increase their knowledge about the use of this treatment in major depression. We emphasize TMS use in common patient populations and discuss the place of TMS in the treatment algorithm of treatment-resistant depression (TRD).
TMS Studies in Depression
TMS has been studied and is widely utilized to treat MDD with a large body of evidence supporting its efficacy.4,5 Three main large randomized controlled clinical trials support the efficacy of TMS for adult patients with major depression. O’Reardon and colleagues examined the efficacy of high frequency TMS in medication free patients with severe major depression (n = 301) with previous medication resistance or medication intolerance. Response rate for TMS was 23.9% versus 12.3% sham (placebo) response (p<.01). Remission rate was 12.2% for TMS and 5.5% for placebo (p = <0.1).6 This study led to the FDA approval of the first TMS protocol in 2008. A NIH-sponsored study using the same protocol in medication-free patients with a history of medication resistance (n = 190) found a 15% response for rTMS and 5% response for sham.7 Remission rates were 14.1% for TMS and 5.5% for sham.7 In 2015 Levkovitz and colleagues examined high frequency Deep TMS, using the H1 coil (n=212). This coils allows for deeper but less focal stimulation in the prefrontal cortex and fiber tracts connecting with subcortical regions. They found a 38.4% response for Deep TMS versus 21.4% for sham in medication-free patients with treatment resistance or treatment intolerance. Remission rates were 32.6% and 14.5% respectively for active deep TMS versus sham deep TMS.8
Studies conducted post-marketing approval in naturalistic settings yielded improved clinical outcomes. Conolly and colleagues examined 100 patients with treatment-resistant depression treated at an academic center. They reported 50.6 % response and a 24.7% remission rate. Notably, this study included a subgroup of patients who previously received ECT, of which 47% responded to TMS.9 Carpenter et. al examined patients with TRD in a multisite naturalistic study (n = 307) and found a 58% response and 37.1% remission rates. In this study, younger age ( < 55 y/o) and lower depression severity at baseline were moderators of TMS response. Interestingly, study patients with high medication resistance were as likely to respond to TMS as those with lower medication resistance. Regarding adherence, the study reported 83% of adherence which is comparable with a 7.7% drop out in the pivotal randomized controlled study.10 Clinical characteristics of this patient population including heterogeneity of illness severity, levels of treatment resistance, greater comorbidities, as well as concomitant antidepressants, may have contributed to the improved outcomes seen in these patients.
In sum, TMS is efficacious for major depression as demonstrated in multiple RCTs and has demonstrated effectiveness in large real-world studies.
TMS in Special Patient Populations
TMS in Patients with Depression and Anxiety
Clinically significant anxiety is a common co-traveler in patients with MDD. Comorbid anxiety may present either as a prominent symptom of the depressive episode, such as complaints of tension, restlessness, worrying, fearfulness of something awful happening, or feelings of loss of control; or as a comorbid anxiety disorder such as generalized anxiety disorder, panic disorder, or social anxiety disorder. In both cases, anxiety is highly common in patients with depression. Furthermore, depression with concurrent anxiety has been associated with greater depressive symptom severity, higher suicide risk, polypharmacy and greater use of benzodiazepines.11 The treatment of MDD with anxiety is challenging in part because these patients experience a greater burden of medication side effects12 and may be anxious about taking their antidepressant medications.
Initial TMS studies found anxiety as a negative predictor of antidepressant response.13 However, recent TMS studies have shown improvement of both depression and anxiety in patients with concurrent anxiety. In a large naturalistic study (n = 248) Clarke and colleagues reported 39.5% antidepressant response for patients with comorbid anxiety disorders treated with TMS. No differences were found between antidepressant response rates in those with or without anxiety comorbidities and symptomatic improvement in anxiety in patients with anxiety disorders was seen.14 An analysis of the randomized non-inferiority THREE-D trial in patients with TRD (n = 288) reported improvement in anxiety symptoms with either standard 10 Hz TMS versus intermittent theta burst TMS (iTBS) to the left Dorsolateral Prefrontal Cortex (DLPFC). Importantly. The study showed depression and anxiety symptoms followed the same trajectory of improvement. The authors posited that modulation of brain structures including the amygdala in the mesocortico-limbic reward circuit may be involved in the anxiety effects of TMS over the DLPFC.15 Recently, a large multisite registry study (n = 1820) showed 50% improvement in generalized anxiety symptoms using the GAD-7 Scales in patients with anxious depression treated with TMS. The study reported the use of off-label TMS protocols consisting of bilateral stimulation to the right DLPFC (using inhibitory frequency) and the left DLPFC ( using excitatory frequency) in patients with anxious depression.16
Conflicting evidence has been reported in the US military veterans population, partly attributed to comorbid Post-Traumatic Stress Syndrome (PTSD). TMS treatment did not separate from placebo in a Randomized Controlled Trial (RCT) in veterans with TRD (n= 164). In this study, PTSD was a moderator of treatment effects with higher remission rates for MDD without comorbid PTSD for active treatment versus sham and lower remission rates for MDD with PTSD.17 By contrast a multisite naturalistic study (n = 770) of veterans with MDD and PTSD found depression improvement with TMS with a large effect size Cohen’s 1.21 (95% CI 1.04–1.21). The presence of PTSD did not impact antidepressant response.18
In summary, TMS is efficacious for major depression with comorbid anxiety with improvement in both depressive and anxiety symptoms. The evidence of TMS in veteran populations with comorbid PTDS is conflicting.
TMS for Adolescent Depression
Similar to MDD observed in adults, adolescent major depression is a major public health problem with immense morbidity and mortality. Suicide is the second leading cause of death for individuals in the US between the ages of 15–24, with most of those cases likely due to MDD. Given the almost two-fold increased prevalence from around 8% to nearly 16% of adolescent depression over the past decade19 and the relatively limited options of FDA-approved treatments for MDD namely fluoxetine and escitalopram, the need for novel therapeutics is at an all-time high.
In early 2024, the FDA granted TMS clearance for depression in adolescents aged 15- to 21-years old. This decision stemmed from real world data on 1,200 adolescents with MDD treated with a specific TMS device. The study showed that 78% of patients had depression improvement and 48% achieved remission with TMS.20 While promising, one limitation includes this analysis being drawn from naturalistic observation as opposed to a rigorous RCT study design. To date, the two RCT of TMS in adolescents produced conflicting results: (1) A study by Pan and colleagues observed treatment-naive MDD patients benefiting from active rTMS with significantly reduced depression scores on the Hamilton Depression rating scale and the Montgomery Asberg Depression scale in comparison to sham rTMS21; whereas (2) data from another randomized trial suggests that TMS is not more effective than sham in a treatment-resistant depression adolescent population.22
From a safety perspective, studies in adolescent patients showed similar to adults that TMS is generally well-tolerated but mild and transient side effects such as headache, scalp discomfort, muscle twitching, fatigue, and tinnitus are common.23 More serious, but rare, side effects include seizures and hearing loss. The seizure risk, estimated to be around 0.6%, is not dissimilar to what is observed in adults receiving TMS or the incidence of spontaneous seizures with antidepressant medications.24
Despite gaining FDA clearance for adjunctive treatment of adolescent depression, there is still need for further investigation of optimal treatment parameters and study design for young patient populations. A majority of studies have localized the treatment region to the dLPFC. However, this does not take into account heterogeneity in depression, severity or specific neurodevelopmental trajectories in this population.21,22 Thus, future studies incorporating the use of brain imaging may promote the identification of other brain regions of interest and pave way for better target engagement in the young. There remains an FDA black box warning for increased suicidality related to antidepressant use in young patients25 which may offer an advantage for utilization of brain stimulation treatments in adolescents. Ultimately, TMS gaining FDA clearance is a pivotal step in expanding upon the limited treatment options for depression adolescents.
TMS for Depression in Older Adults
Late-life depression (LLD) is defined as major depression in adults aged 60 and older. LLD affects a significant portion of the aging population with a reported prevalence of 2.7% in elderly men and 4.4% in elderly women.26 Notably up to 30% of patients with LLD do not achieve response to conventional antidepressant therapies.27 This highlights a substantial need for more safe and effective treatments. TMS is particularly appealing in this population due to its favorable safety profile and non-pharmacologic mechanism, which is critical given the increased risk of adverse drug interactions from polypharmacy and agerelated physiological changes.3
LLD is a multifactorial disease with marked biological heterogeneity; some individuals with LLD have preserved brain structure, while many—particularly those with resistant depression—have age-related changes, such as vascular and metabolic dysfunction, chronic inflammation, stress, and the accumulation of iron and beta-amyloid.28 These changes contribute to accelerated brain aging, structural and functional brain alterations.29 Cognitive impairments, particularly in executive function, are also common in LLD and are associated with reduced responsiveness to oral antidepressants, greater risk of treatment discontinuation, and higher likelihood of symptom recurrence or early relapse.27,30 In contrast, preliminary evidence suggests that comorbid cognitive impairment does not reduce the response rate in LLD from TMS.31 Treatment of LLD is further compounded by medical comorbidities including cardiovascular disease, diabetes, cancer, and neurologic and other comorbid psychiatric conditions observed in this population.32 These overlapping biological, cognitive, and systemic processes make the pharmacological treatment of LLD particularly challenging.
It has been posited that TMS mechanism entails modulation of activity on brain networks disrupted in depression.33 Such networks have been identified using modern resting state functional MRI techniques measuring the blood oxygen level dependent (BOLD) signal.34 Key resting state networks thought to be dysregulated in geriatric depression include: the Cognitive Control Network (CCN) a fronto-parietal circuit involved in top-down attention dependent-executive control which has been associated with the executive-dysfunction syndrome in LLD,35 and the Default Mode Network (DMN) implicated in self-referential processes and thought to be overactive in depression.35,36 Low resting state connectivity in the CCN and high resting state connectivity in the DMN have been reported in LLD.37 However, initial data examining the effects of intermittent theta burst TMS (iTBS) on the CCN and the DMN did not detect changes before and after iTBS in older adults with depression.38
TMS is FDA-approved for the treatment of geriatric depression up to age 68, with one device cleared for use in up to age 86.3 Initial open-label studies reported response rates to TMS ranging from 20–50% in geriatric populations.39 Newer protocols show improved outcomes. Trevizol and colleagues analyzed data from RCTs and reported remission rates of 40% using bilateral TMS with stimulation over both left and right dorsolateral prefrontal cortices compared to unilateral TMS (0%) and sham TMS (0%).40 A randomized non-inferiority trial showed non-inferiority of bilateral iTBS compared bilateral standard TMS, with remission rates of 35% for bilateral iTBS versus 32.9% remission rate for bilateral TMS.41 Additionally, deep TMS (using the H1 coil) has shown significantly greater remission (40%) rate compared to sham 14.8% and no serious adverse events.42
Overall while current data and FDA approvals support the effectiveness of TMS in LLD, additional research can help optimize treatment outcomes. These include addressing coil to cortex distance in individuals with marked cortical atrophy, stimulation parameters and laterality and target engagement precision using resting state brain connectivity.43
Overview of TMS Safety
TMS is generally considered safe and well-tolerated when standard procedures and guidelines are followed. The most common side effects are stimulation site pain (39%), tension-type headaches (28–65%), nausea (7–11%), and dizziness (4–9%). Severe adverse effects including seizures, syncope, and hearing impairment are uncommon.3 The incidence of seizures with TMS is low (less than 1%) and primarily occurs in individuals with known risk factors such as severe head trauma, non-treated epilepsy, heavy alcohol use, severe cardiac disease, medications that lower seizure threshold, sleep deprivation, and electrolyte disturbances.44 Those administering TMS should be educated in seizure recognition and trained in basic life support to maintain the safety of the patient in case of seizure, besides clinical practices should develop and follow standard protocols to manage for this serious but rare event.3 Syncope which can also present with motor phenomena such as tonic postures of myoclonic jerks has also been reported in some patients and is a benign occurrence typically related to anxiety, vasovagal response, or discomfort.3
Hearing protection (eraplugs) is required due to the loud acoustic artifact produced by TMS.45 Permanent changes in hearing threshold were observed in an individual without hearing protection, by contrast in the majority of studies where hearing protection was used, no changes in hearing were observed.45 Reported side effects were generally limited to discomfort and transient tinnitus, with no permanent hearing damage noted.46
Compared to electroconvulsive therapy, TMS has a more favorable safety profile, particularly regarding cognitive effects.47 Most studies report no significant cognitive impairment associated with TMS and some patients may experience transient improvements in both short and long term memory.47 Although rare (0.84% per year), cases of TMS-induced mania or hypomania have been documented, especially in patients with a history of bipolar disorder.3 No consistent pattern of long-term side effects has been identified with the use of TMS.3 TMS is contraindicated in patients with metallic implants in or near the head, including cochlear implants or medication pumps.48 While initially thought to be a contraindication, pacemakers and ICDs are considered safe if there is sufficient distance (> 10 cm) between these devices and the TMS coil.46 Great caution is taken in patients with pacemakers or ICDs to mitigate risk of TMS disrupting these devices’ function. Those with a personal history of epilepsy or traumatic brain injury are at higher risk of epileptic seizure.45
Overall, TMS is associated with minor side effects that typically resolve within a few days; more serious adverse effects are uncommon and can be minimized through proper patient screening and adherence to established protocols.
Clinically-Used TMS Protocols
The effects of TMS on the brain vary widely depending on the stimulation protocol, which refers to the specific set of parameters used during treatment.3 These include pulse frequency (pulses per second), pulse pattern, intensity (typically relative to the motor threshold), number of pulses continuously before a pause (pulse train), duration, and treatment schedule.3,46 TMS is usually delivered in trains of stimulation for clinical purposes, therefore it is also known as repetitive TMS or rTMS. Broadly, TMS protocols fall into two categories: fixed-frequency stimulation (either high- or low-frequency) and patterned protocols such as theta burst stimulation (TBS), in which pulses are delivered in bursts. These variables influence the excitatory or inhibitory effects on the brain of TMS and are tailored to specific clinical and research goals.46,49
The conventional FDA-approved TMS protocol for the treatment of MDD involves high-frequency stimulation delivered to the left dorsolateral prefrontal cortex (DLPFC). This standard regimen consists of 10 Hz stimulation administered over a 37.5-minute session delivering 3,000 pulses per session, typically five days a week for four to six weeks.6 High-frequency TMS (greater than 1 Hz) is thought to exert an excitatory effect on cortical neurons. In contrast, low-frequency TMS (1 Hz or less) is typically associated with inhibitory effects.49 While effective, the conventional high-frequency protocol (37.5-minute duration per session) is time-intensive, restricts capacity, and contributes to higher treatment costs.50 These logistical challenges have spurred interest in the development and adoption of shorter protocols such as Theta Burst TMS (TBS).
TBS is an efficient TMS protocol that substantially reduces treatment duration from 37.5 minutes to three minutes per session while producing equivalent antidepressant responses. TBS is designed to mimic endogenous theta rhythms, which can induce synaptic long-term potentiation. One form of TBS, intermittent TBS (iTBS), delivers 600 pulses over a three-minute period and has demonstrated non-inferior response (49%) and remission (32%) rates compared to conventional 10 Hz stimulation (47% response and 27% remission).50 Compared to 10 Hz rTMS, iTBS had no significant differences in self-reported adverse events following treatment and had similarly low dropout rates.50
Recently developed, the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) is an innovative, accelerated TMS protocol that intensifies the delivery of iTBS. The protocol administers a total of 90,000 pulses over the course of five consecutive days, with patients receiving 10 iTBS sessions per day. Each session is brief, three minutes, with 50-minute intersession intervals.51 A key component of SAINT is its use of functional connectivity MRI (fcMRI) personalized targeting. Utilizing fcMRI data for each individual, this approach identifies a region of the DLPFC that is functionally anti-correlated with the subgenual anterior cingulate cortex,51 which is thought to be dysregulated in depression.33 This innovative protocol tested under open label conditions resulted in high remission rates (80–90%) with minimal side effects and no reported seizures51 and subsequently obtained FDA clearance (09/2022) for the treatment of MDD.
TMS in the Depression Treatment Algorithm: Addressing the Challenge of Treatment-Resistant Depression
A treatment algorithm is helpful for directing treatment of depression; for example, start with an SSRI and then if no response, move to a medication from a different class (e.g., serotonin norepinephrine reuptake inhibitor such as duloxetine). Challenges arise in the case of treatment resistant depression (TRD); i.e., two failed trials of antidepressants in the current episode of major depression. TRD is common, with an estimate of about one-third of all individuals with major depression being treatment resistant.52 TRD it also is associated with persistent suffering, suicide risk, and high societal costs including burden on the health care system, unemployment, and individual productivity.53 Increasing evidence suggests that further pharmacological strategies are insufficient to address this problem. In the Sequenced Treatment Alternatives to Relieve Depression STAR-D trial—the largest clinical trial of antidepressant—after two failed trials of different antidepressant classes, only 13.7% and 13.0% of patients remitted from a third or fourth trial, respectively.54 More recent data in LLD show a similar diminishing rate of returns: in people with TRD, remission rates from augmentation and switch strategies ranged from 19–29%, with further diminished response in patients with three or more failed trials.55,56 Patients with TRD need better options than additional medication trials that are likely to be futile.
Many studies support the use of TMS in TRD. The FDA cleared TMS for patient with previous antidepressant failures as well as for those with medication intolerance. Given the increased complexity in the treatment of depression an important question remains: when TMS should be considered? Two recent studies have informed on the comparative effectiveness of TMS and other treatment options. The first is the ASCERTAIN-TRD study which randomized patients with TRD to three conditions: antidepressant medication switch, antidepressant augmentation with the atypical antipsychotic aripiprazole (a popular augmentation option in major depression), or addition of TMS. TMS showed greater depression improvement than medication switch. TMS had also higher response and remission rates than aripiprazole augmentation.57 In the second study, Dalhuisen and colleagues randomized patients with TRD to TMS versus algorithm-based pharmacological treatment (i.e., switch to a tricyclic, augmentation with lithium, or atypical antipsychotic). Both groups received psychotherapy. TMS showed greater depression improvement than the pharmacotherapy group with large effect size (Cohen’s d = −0.77).58 Headaches, tiredness, and local pain were reported with TMS, whereas headache, tiredness, dizziness, dry mouth, sleep problems, weight gain, and diarrhea occurred with medications.58
Clinical Vignette.
Initial presentation and Treatment Resistant Histor y
A 72-year-old, single male academic musician was referred for TMS evaluation for worsening depression for over a year. He reported persistent depressed mood most days, he had lost interested in music and in reading, and stopped going to the gym. He experienced frequent thoughts of death, and he was feeling increasingly isolated. He endorsed fatigue, hypersomnia, and poor concentration which interfered with his job. He reported frequent worries and vasomotor symptoms including hot flashes. He had been planning on retiring from his academic position, his longterm partner moved to another city and he had acquired additional responsibilities in caring for his elderly mother.
The patient had a previous diagnosis of depression and anxiety. He has been attending psychotherapy for over a decade. His primary care physician prescribed fluoxetine and paroxetine for years but they ultimately stopped working. His psychiatrist prescribed bupropion 300mg/day and Cymbalta 60mg/day. Bupropion was discontinued due to irritability. Cymbalta was increased to 90mg/day and buspirone 30mg BID and lorazepam 0.5mg PRN were added. His history was notable for a period of increased alcohol intake (several days a week) during the COVID pandemic. In the last year he managed to reduce his drinking to two to three times per week. He had never blacked out or had withdrawal symptoms.
He was in good physical health but had controlled hypertension, hyperlipidemia, coronary artery disease post-stenting 20 years ago, paroxysmal atrial fibrillation, sleep apnea using CPAP. He had no history of seizures, head trauma or implanted metallic devices on the head. On mental status he presented neatly groomed with normal psychomotor activity, his mood was described as “not so good” and exhibited a dysthymic affect. There was no evidence of suicidal ideation or psychosis. He was fully oriented, and no cognitive deficits were noted.
Treatment and Outcom e
The patient underwent intermittent theta burst stimulation with triplet 50Hz burst repeated at 5Hz, delivering 600 pulses for over three minutes, with sessions five days/week for six weeks (30 sessions) and a taper over the next three weeks. Medications were held fixed without changes during TMS.
At the end of treatment, he reported improved mood and motivation. He had a better outlook on his retirement plans and was at ease with the timeline and was exploring potential commitments in his field for after his retirement. He was more social, going out for dinner, and reaching out to friends by phone. He reported improved energy and concentration describing this as if “the brain fog is being lifted.” He no longer had thought of death and felt more hopeful about the future. Notably He was able to further reduce his alcohol intake.
As a whole, these studies in TRD show that, when compared to pharmacotherapy TMS leads to clinically meaningful outcomes and shows a favorable side effect profile. TMS should be considered after two failed antidepressant treatment trials and certainly after three failed trials. ECT can also be considered for TRD or for those in need of a rapid antidepressant response (e.g., suicidal ideation, weight loss) or with psychosis. Additional studies are needed to refine and test treatment algorithms in TRD including the role of psychopharmacological and neuromodulation interventions. (Figure 2 and Clinical Vignette).
Figure 2.
Depression scores during TMS treatment using the Patient Health Questionnaire PHQ 9 (decreasing scores denote improvement)
Conclusion
TMS is an effective, a safe and well-tolerated brain stimulation treatment for MDD. Its use is supported by a large research evidence including RCTs and effectiveness data in real world patients. TMS in special populations shows improvement of depression and anxiety in these comorbid conditions. TMS is safe and effective in adolescent depression with recently granted FDA approval. Older adults with depression respond to TMS with bilateral and deep TMS protocols showing improved responses. Novel protocols such as iTBS have comparable efficacy to standard TMS with improved efficiency. Accelerated protocols such as SAINT offer a highly precise treatment approach with improved outcomes. In the sequential treatment algorithm of depression, TMS shows greater benefit than medication and should be considered after two failed antidepressant medications trials.
Footnotes
Pilar Cristancho, MD, (pictured), is in the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. Jeanne Therese Hagemeister, MS, is at Creighton University School of Medicine, Omaha, Nebraska, USA. Darin Quach, DO, PhD, is in the Department of Psychiatry, Child Division, Washington University School of Medicine, St. Louis, Missouri, USA. Eric J. Lenze, MD, is in the Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
Disclosure: No financial disclosures reported. Artificial intelligence, language models, machine learning, or similar technologies were not used in the conceptualization, study, research, preparation, or writing of this manuscript.
References
- 1.Ridding MC, Rothwell JC. Is there a future for therapeutic use of transcranial magnetic stimulation? Nat Rev Neurosci. 2007 Jul;8(7):559–67. doi: 10.1038/nrn2169. [DOI] [PubMed] [Google Scholar]
- 2.Barker AT. An introduction to the basic principles of magnetic nerve stimulation. J Clin Neurophysiol. 1991 Jan;8(1):26–37. doi: 10.1097/00004691-199101000-00005. [DOI] [PubMed] [Google Scholar]
- 3.Trapp NT, Purgianto A, Taylor JJ, et al. Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. Clin Neurophysiol. 2025 Feb;170:206–233. doi: 10.1016/j.clinph.2024.12.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Dalhuisen I, van Bronswijk S, Bors J, et al. The association between sample and treatment characteristics and the efficacy of repetitive transcranial magnetic stimulation in depression: A meta-analysis and meta-regression of sham-controlled trials. Neurosci Biobehav Rev. 2022 Oct;141:104848. doi: 10.1016/j.neubiorev.2022.104848. [DOI] [PubMed] [Google Scholar]
- 5.Li H, Cui L, Li J, Liu Y, Chen Y. Comparative efficacy and acceptability of neuromodulation procedures in the treatment of treatment-resistant depression: a network meta-analysis of randomized controlled trials. J Affect Disord. 2021 May 15;287:115–124. doi: 10.1016/j.jad.2021.03.019. [DOI] [PubMed] [Google Scholar]
- 6.O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007 Dec 1;62(11):1208–16. doi: 10.1016/j.biopsych.2007.01.018. [DOI] [PubMed] [Google Scholar]
- 7.George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a shamcontrolled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507–16. doi: 10.1001/archgenpsychiatry.2010.46. [DOI] [PubMed] [Google Scholar]
- 8.Levkovitz Y, Isserles M, Padberg F, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015 Feb;14(1):64–73. doi: 10.1002/wps.20199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Connolly KR, Helmer A, Cristancho MA, Cristancho P, O’Reardon JP. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry. 2012 Apr;73(4):e567–73. doi: 10.4088/JCP.11m07413. [DOI] [PubMed] [Google Scholar]
- 10.Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012 Jul;29(7):587–96. doi: 10.1002/da.21969. [DOI] [PubMed] [Google Scholar]
- 11.Dold M, Bartova L, Souery D, et al. Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. J Psychiatr Res. 2017 Aug;91:1–13. doi: 10.1016/j.jpsychires.2017.02.020. [DOI] [PubMed] [Google Scholar]
- 12.Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008 Mar;165(3):342–51. doi: 10.1176/appi.ajp.2007.06111868. [DOI] [PubMed] [Google Scholar]
- 13.Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology. 2009 Jan;34(2):522–34. doi: 10.1038/npp.2008.118. [DOI] [PubMed] [Google Scholar]
- 14.Clarke E, Clarke P, Gill S, Paterson T, Hahn L, Galletly C. Efficacy of repetitive transcranial magnetic stimulation in the treatment of depression with comorbid anxiety disorders. J Affect Disord. 2019 Jun 1;252:435–439. doi: 10.1016/j.jad.2019.03.085. [DOI] [PubMed] [Google Scholar]
- 15.Trevizol AP, Downar J, Vila-Rodriguez F, Konstantinou G, Daskalakis ZJ, Blumberger DM. Effect of repetitive transcranial magnetic stimulation on anxiety symptoms in patients with major depression: An analysis from the THREE-D trial. Depress Anxiety. 2021 Mar;38(3):262–271. doi: 10.1002/da.23125. [DOI] [PubMed] [Google Scholar]
- 16.Hutton TM, Aaronson ST, Carpenter LL, et al. The Anxiolytic and Antidepressant Effects of Transcranial Magnetic Stimulation in Patients With Anxious Depression. J Clin Psychiatry. 2023 Jan 11;84(1) doi: 10.4088/JCP.22m14571. [DOI] [PubMed] [Google Scholar]
- 17.Yesavage JA, Fairchild JK, Mi Z, et al. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial. JAMA Psychiatry. 2018 Sep 1;75(9):884–893. doi: 10.1001/jamapsychiatry.2018.1483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Madore MR, Kozel FA, Williams LM, et al. Prefrontal transcranial magnetic stimulation for depression in US military veterans - A naturalistic cohort study in the veterans health administration. J Affect Disord. 2022 Jan 15;297:671–678. doi: 10.1016/j.jad.2021.10.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wilson S, Dumornay NM. Rising Rates of Adolescent Depression in the United States: Challenges and Opportunities in the 2020s. J Adolesc Health. 2022 Mar;70(3):354–355. doi: 10.1016/j.jadohealth.2021.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Erin B. FDA Clears Neurostar TMS for Treatment of MDD in Adolescents. [Accessed 8/31/25];Psychiatric Times. 2025 https://www.psychiatrictimes.com/view/fda-clears-neurostar-tms-for-treatment-of-mdd-in-adolescents . [Google Scholar]
- 21.Pan F, Shen Z, Jiao J, et al. Neuronavigation-Guided rTMS for the Treatment of Depressive Patients With Suicidal Ideation: A Double-Blind, Randomized, Sham-Controlled Trial. Clin Pharmacol Ther. 2020 Oct;108(4):826–832. doi: 10.1002/cpt.1858. [DOI] [PubMed] [Google Scholar]
- 22.Croarkin PE, Elmaadawi AZ, Aaronson ST, et al. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. Neuropsychopharmacology. 2021 Jan;46(2):462–469. doi: 10.1038/s41386-020-00829-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Krishnan C, Santos L, Peterson MD, Ehinger M. Safety of noninvasive brain stimulation in children and adolescents. Brain Stimul. 2015 Jan-Feb;8(1):76–87. doi: 10.1016/j.brs.2014.10.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wu CS, Liu HY, Tsai HJ, Liu SK. Seizure Risk Associated With Antidepressant Treatment Among Patients With Depressive Disorders: A Population-Based Case-Crossover Study. J Clin Psychiatry. 2017 Nov/Dec;78(9):e1226–e1232. doi: 10.4088/JCP.16m11377. [DOI] [PubMed] [Google Scholar]
- 25.M-A J. Ten years after the FDA black box warning for antidepressant drugs: A critical narrative review. Archives of Clinical Psychiatry. 2016;43(3):60–66. [Google Scholar]
- 26.Steffens DC, Skoog I, Norton MC, et al. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry. 2000 Jun;57(6):601–7. doi: 10.1001/archpsyc.57.6.601. [DOI] [PubMed] [Google Scholar]
- 27.Subramanian S, Oughli HA, Gebara MA, Palanca BJA, Lenze EJ. Treatment-Resistant Late-Life Depression: A Review of Clinical Features, Neuropsychology, Neurobiology, and Treatment. Psychiatr Clin North Am. 2023 Jun;46(2):371–389. doi: 10.1016/j.psc.2023.02.008. [DOI] [PubMed] [Google Scholar]
- 28.Lindenberger U. Human cognitive aging: corriger la fortune? Science. 2014 Oct 31;346(6209):572–8. doi: 10.1126/science.1254403. [DOI] [PubMed] [Google Scholar]
- 29.Wen J, Fu CHY, Tosun D, et al. Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry. 2022 May 1;79(5):464–474. doi: 10.1001/jamapsychiatry.2022.0020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Cristancho P, Lenze EJ, Dixon D, et al. Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression. J Clin Psychiatry. 2018 May/Jun;79(3) doi: 10.4088/JCP.16m11371. [DOI] [PubMed] [Google Scholar]
- 31.Göke K, McClintock SM, Mah L, et al. Cognitive Profiles in Treatment-Resistant Late-Life Depression and Their Impact on Treatment Outcomes. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Nov;9(11):1199–1210. doi: 10.1016/j.bpsc.2024.07.009. [DOI] [PubMed] [Google Scholar]
- 32.Steffens DC. Treatment-Resistant Depression in Older Adults. N Engl J Med. 2024 Feb 15;390(7):630–639. doi: 10.1056/NEJMcp2305428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Fox MD, Halko MA, Eldaief MC, Pascual-Leone A. Measuring and manipulating brain connectivity with resting state functional connectivity magnetic resonance imaging (fcMRI) and transcranial magnetic stimulation (TMS) Neuroimage. 2012 Oct 1;62(4):2232–43. doi: 10.1016/j.neuroimage.2012.03.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Damoiseaux JS, Rombouts SA, Barkhof F, et al. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13848–53. doi: 10.1073/pnas.0601417103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Tadayonnejad R, Ajilore O. Brain network dysfunction in late-life depression: a literature review. J Geriatr Psychiatry Neurol. 2014 Mar;27(1):5–12. doi: 10.1177/0891988713516539. [DOI] [PubMed] [Google Scholar]
- 36.Sheline YI, Barch DM, Price JL, et al. The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1942–7. doi: 10.1073/pnas.0812686106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Alexopoulos GS, Hoptman MJ, Kanellopoulos D, Murphy CF, Lim KO, Gunning FM. Functional connectivity in the cognitive control network and the default mode network in late-life depression. J Affect Disord. 2012 Jun;139(1):56–65. doi: 10.1016/j.jad.2011.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Cristancho P, Arora J, Nishino T, et al. A pilot randomized sham controlled trial of bilateral iTBS for depression and executive function in older adults. Int J Geriatr Psychiatry. 2023 Jan;38(1):e5851. doi: 10.1002/gps.5851. [DOI] [PubMed] [Google Scholar]
- 39.Gálvez V, Ho KA, Alonzo A, Martin D, George D, Loo CK. Neuromodulation therapies for geriatric depression. Curr Psychiatry Rep. 2015 Jul;17(7):59. doi: 10.1007/s11920-015-0592-y. [DOI] [PubMed] [Google Scholar]
- 40.Trevizol AP, Goldberger KW, Mulsant BH, et al. Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant late-life depression. Int J Geriatr Psychiatry. 2019 Jun;34(6):822–827. doi: 10.1002/gps.5091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Blumberger DM, Mulsant BH, Thorpe KE, et al. Effectiveness of Standard Sequential Bilateral Repetitive Transcranial Magnetic Stimulation vs Bilateral Theta Burst Stimulation in Older Adults With Depression: The FOUR-D Randomized Noninferiority Clinical Trial. JAMA Psychiatry. 2022 Sep 21; doi: 10.1001/jamapsychiatry.2022.2862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Kaster TS, Daskalakis ZJ, Noda Y, et al. Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacology. 2018 Oct;43(11):2231–2238. doi: 10.1038/s41386-018-0121-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Cappon D, den Boer T, Jordan C, Yu W, Metzger E, Pascual-Leone A. Transcranial magnetic stimulation (TMS) for geriatric depression. Ageing Res Rev. 2022 Feb;74:101531. doi: 10.1016/j.arr.2021.101531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Stultz DJ, Osburn S, Burns T, Pawlowska-Wajswol S, Walton R. Transcranial Magnetic Stimulation (TMS) Safety with Respect to Seizures: A Literature Review. Neuropsychiatr Dis Treat. 2020;16:2989–3000. doi: 10.2147/ndt.S276635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008–2039. doi: 10.1016/j.clinph.2009.08.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Chen L, Fukuda AM, Jiang S, et al. Treating Depression With Repetitive Transcranial Magnetic Stimulation: A Clinician’s Guide. Am J Psychiatry. 2025 Jun 1;182(6):525–541. doi: 10.1176/appi.ajp.20240859. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Micallef-Trigona B. Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis. Depress Res Treat. 2014;2014:135049. doi: 10.1155/2014/135049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Taylor R, Galvez V, Loo C. Transcranial magnetic stimulation (TMS) safety: a practical guide for psychiatrists. Australas Psychiatry. 2018 Apr;26(2):189–192. doi: 10.1177/1039856217748249. [DOI] [PubMed] [Google Scholar]
- 49.Miron JP, Jodoin VD, Lespérance P, Blumberger DM. Repetitive transcranial magnetic stimulation for major depressive disorder: basic principles and future directions. Ther Adv Psychopharmacol. 2021;11:20451253211042696. doi: 10.1177/20451253211042696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised noninferiority trial. Lancet. 2018 Apr 28;391(10131)(18):1683–1692. 30295–2. doi: 10.1016/s0140-6736. [DOI] [PubMed] [Google Scholar]
- 51.Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. Am J Psychiatry. 2020 Aug 1;177(8):716–726. doi: 10.1176/appi.ajp.2019.19070720. [DOI] [PubMed] [Google Scholar]
- 52.Sackeim HA, Aaronson ST, Bunker MT, et al. The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF) J Psychiatr Res. 2019 Jun;113:125–136. doi: 10.1016/j.jpsychires.2019.03.021. [DOI] [PubMed] [Google Scholar]
- 53.Zhdanava M, Pilon D, Ghelerter I, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. J Clin Psychiatry. 2021 Mar 16;82(2) doi: 10.4088/JCP.20m13699. [DOI] [PubMed] [Google Scholar]
- 54.Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905–17. doi: 10.1176/ajp.2006.163.11.1905. [DOI] [PubMed] [Google Scholar]
- 55.Lenze EJ, Mulsant BH, Roose SP, et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N Engl J Med. 2023 Mar 23;388(12):1067–1079. doi: 10.1056/NEJMoa2204462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Kim HK, Karp JF, Lavretsky H, et al. Moderators of antidepressant augmentation versus switch in the OPTIMUM randomised controlled trial. Br J Psychiatry. 2025 Jun 19;:1–8. doi: 10.1192/bjp.2025.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Papakostas GI, Trivedi MH, Shelton RC, et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug;29(8):2287–2295. doi: 10.1038/s41380-024-02468-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Dalhuisen I, van Oostrom I, Spijker J, et al. rTMS as a Next Step in Antidepressant Nonresponders: A Randomized Comparison With Current Antidepressant Treatment Approaches. Am J Psychiatry. 2024 Sep 1;181(9):806–814. doi: 10.1176/appi.ajp.20230556. [DOI] [PubMed] [Google Scholar]



